Orphan drugs and rare diseases: current landscape, challenges, and future prospects

Arun Kumar Rai; Shayam Singh Maina; Monika Kourav; Amrit Lal Patel

doi:10.22376/ijpbs.v17i1.164

Authors

Arun Kumar Rai Assistant Professor, Department of Pharmaceutical Chemistry, Corporate Institute of Pharmacy, Bhopal, Madhya Pradesh, India. (462022)
Shayam Singh Maina Assistant Professor, Surabhi College of Pharmacy, Bhopal Madhya Pradesh, India. (462022)
Monika Kourav Assistant Professor, Surabhi College of Pharmacy, Bhopal Madhya Pradesh, India. (462022)
Amrit Lal Patel Ph. D. Research Scholar, Parul University, Vadodara Gujrat, India

Abstract

One of the most exciting and revolutionary areas of contemporary pharmaceutical development is orphan pharmaceuticals, therapeutic compounds intended to cure uncommon diseases affecting fewer than 200,000 people in the United States (or comparable populations in other regions). The market for orphan drugs is expected to increase at a compound annual growth rate (CAGR) of 10.94% from its estimated USD 236.27 billion in 2025 to USD 667.48 billion by 2035. This impressive development trajectory is a result of supporting regulatory frameworks, advances in precision medicine and genetic research, and the rising incidence of rare diseases globally. However, the landscape of orphan drugs poses significant obstacles, such as extraordinarily high development and per-patient treatment costs, tiny patient populations that make clinical trial enrollment difficult, and complex regulatory procedures across several jurisdictions.This thorough analysis looks at the state of rare diseases and orphan medications now, summarizes what is known about development obstacles, and considers potential avenues for therapeutic innovation in the future. The study covers market dynamics, legislative implications, technology developments such as gene and cell therapies, regulatory processes and incentives, and clinical trial design concerns. This review offers insights for pharmaceutical researchers, legislators, patient advocacy organizations, and medical professionals involved in managing rare diseases by combining contemporary literature and market statistics.

Keywords:

orphan drugs, rare diseases, gene therapy, cell therapy, regulatory frameworks, clinical trials, precision medicine, market dynamics, unmet medical needs

DOI

https://doi.org/10.22376/ijpbs.v17i1.164

References

1. Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, Ravinandan ME, Ramchandran R, Haldar K, Lin JC, Babar IA. Organization for rare diseases India (ORDI)–Addressing the challenges and opportunities for the Indian rare diseases' community. Genetics research. 2014 Jan;96:e009.

2. Brooks PJ, Grady AC, Groft S, Ho L, Lumsden J, Shah M, Sid E, Xu Y, Tisdale A, Dickens J, Pichard D. The division of rare diseases research innovation at the national center for advancing translational sciences, NIH: mission, history, and current research activities. Rare Dis Orphan Drug J. 2024 Jun 3;3(02):15.

3. Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease characteristics on research methodology. Orphanet journal of rare diseases. 2018 Jan 19;13(1):14.

4. Iyer K, Tenchov R, Sasso J, Ralhan K, Jotshi J, Polshakov D, Maind A, Zhou QA. Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research.

5. Abdallah S, Sharifa M, Almadhoun MK, Khawar Sr MM, Shaikh U, Balabel KM, Saleh I, Manzoor A, Mandal AK, Ekomwereren O, Khine WM. The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders. Cureus. 2023 Oct 11;15(10).

6. Han Q, Fu H, Chu X, Wen R, Zhang M, You T, Fu P, Qin J, Cui T. Research advances in treatment methods and drug development for rare diseases. Frontiers in Pharmacology. 2022 Oct 12;13:971541.

7. Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: development trends and strategies. Journal of Pharmacy and Bioallied Sciences. 2010 Oct 1;2(4):290-9.

8. Morel T. Rare diseases and orphan drugs: patient values, market trends and misconceptions.

9. IJINU TP, MOHANDAS N, SALONI A, PUSHPANGADAN P. SCIENTIFIC VALIDATION OF TRADITIONAL KNOWLEDGE: DEVELOPMENT OF HERBAL DRUGS AND EXPLORATION OF LEADS FOR MODERN DRUG DISCOVERY. Traditional Medicines in Drug Discovery and Development. 2024 Jul 18:10.

10. Wechsler J. ORPHAN DRUG SURGE RAISES REGULATORY AND DEVELOPMENT CHALLENGES. Applied Clinical Trials. 2017 Apr 1;26(4/5):7.

11. Franck R. Mastering Strategic Marketing For Specialty Pharmaceuticals: A Hands-on Guide. World Scientific; 2025 Jul 8.

12. Jung J, Choi YH. Exploring Novel Drug Development: Insights from Orphan Drug Research. Korea Institute for Industrial Economics and Trade Research Paper No. 2024 Feb 21;23.

13. Jung J, Choi YH. Exploring Novel Drug Development: Insights from Orphan Drug Research. Korea Institute for Industrial Economics and Trade Research Paper No. 2024 Feb 21;23.

14. Debnath A, Mazumder R, Mazumder A, Tyagi PK, Singh RK. Challenges and progress of orphan drug development for rare diseases. Current Pharmaceutical Biotechnology. 2025.

15. Challener C. FDA New Drug Approvals Down Significantly in 2016.

16. Umoh I, Mustapha A, Pharm B. Global Strategies for the Commercialization of Rare and Ultra-Rare Disease Therapies.

17. Jonker AH, O’Connor D, Cavaller-Bellaubi M, Fetro C, Gogou M, ’T Hoen PA, de Kort M, Stone H, Valentine N, Pasmooij AM. Drug repurposing for rare: progress and opportunities for the rare disease community. Frontiers in medicine. 2024 Jan 17;11:1352803.

18. Liu J, Barrett JS, Leonardi ET, Lee L, Roychoudhury S, Chen Y, Trifillis P. Natural history and real‐world data in rare diseases: applications, limitations, and future perspectives. The Journal of Clinical Pharmacology. 2022 Dec;62:S38-55.

19. Kitahara K, Kano S. Assessing rare disease understanding: a novel disease readiness level framework. Orphanet Journal of Rare Diseases. 2025 Dec 29;20(1):628.

20. Monge AN, Sigelman DW, Temple RJ, Chahal HS. Use of US Food and Drug Administration expedited drug development and review programs by orphan and nonorphan novel drugs approved from 2008 to 2021. JAMA Network Open. 2022 Nov 1;5(11):e2239336-.

21. NS P, MUNDRA S, LOPES NM, DUBEY A. FAST-TRACKING DRUG APPROVALS: A SYSTEMATIC REVIEW OF THE US FDA'S EXPEDITED REGULATORY PATHWAYS. Int J App Pharm. 2025;17(5):1-8.

22. Windfuhr F, Larsson K, Framke T, Lasch F. Which clinical trial designs and statistical approaches have been used in assessments of orphan maintenance by the European Medicines Agency between 2012 and 2022? A cross-sectional study. BMJ open. 2024 Dec 1;14(12):e086171.

23. Attwood MM, Rask-Andersen M, Schiöth HB. Orphan drugs and their impact on pharmaceutical development. Trends in pharmacological sciences. 2018 Jun 1;39(6):525-35.

24. Marques TM. Trends in innovative technologies in pharma (2000 to 2050) (Doctoral dissertation).

25. Ambery P, Kilcoyne A, O'Connor D. Pharmaceutical Medicine. Oxford University Press; 2025 Nov 30.

26. Umoh I, Mustapha A, Pharm B. Global Strategies for the Commercialization of Rare and Ultra-Rare Disease Therapies.

27. Franck R. Mastering Strategic Marketing For Specialty Pharmaceuticals: A Hands-on Guide. World Scientific; 2025 Jul 8.

28. De Stefano M, van Olden R, Arjmand E, Nam J, de Fries Jensen L, Schäfer B, Kirschner J, Ferlini A, Blankart CR, Cassidy R. Economic evaluation of next-generation sequencing technologies in paediatric patient groups with confirmed or possible rare diseases: A systematic literature review. Genetics in Medicine. 2025 Dec 2:101655.

29. Wechsler J. ORPHAN DRUG SURGE RAISES REGULATORY AND DEVELOPMENT CHALLENGES. Applied Clinical Trials. 2017 Apr 1;26(4/5):7.